PIK3CA and ARID1A may be targets for drug development in recurrent or metastatic cervical cancer, according to research presented at the 2023 SGO Annual Meeting on Women’s Cancer.
For this study, researchers analyzed data from 452 patients with metastatic or recurrent cervical cancer who were enrolled on the GOG 0240 trial (ClinicalTrials.gov Identifier: NCT00803062).
The patients provided 112 tumor samples with sufficient DNA and RNA for mutational analysis. The researchers identified more than 35,917 mutations in these samples.
PIK3CA was mutated in 25% of samples (28/112 patients). This is similar to the frequency of PIK3CA mutations seen in early-stage cervical cancer cases from The Cancer Genome Atlas (TCGA).
On the other hand, the researchers found a significantly higher frequency of ARID1A mutations in the GOG-240 samples (17%; 19/112 patients) than in the TCGA data (5%; P <.005).
The researchers also compared overall survival (OS) and progression-free survival (PFS) among patients with and without mutations in PIK3CA and ARID1A.
The median OS was 15.4 months in patients with PIK3CA mutations and 16.2 months in patients without them (hazard ratio [HR], 1.0; 95% CI, 0.61-1.62). The median PFS was 7.5 months and 6.1 months, respectively (HR, 0.85; 95% CI, 0.54-1.34).
The median OS was 14.3 months in patients with ARID1A mutations and 17.1 months in patients without them (HR, 1.18; 95% CI, 0.67-2.06). The median PFS was 5.3 months and 6.9 months, respectively (HR, 1.0; 95% CI, 0.59-1.68).
“Both ARID1A and PIK3CA are potential targets and could be considered for drug development through clinical trials in cervical cancer,” said study presenter Anjali Hari, MD, of the University of California, Irvine.
Disclosures: Dr Hari reported having no conflicts of interest.
Hari A, Sill MW, Monk BJ, et al. PIK3CA and ARID1A mutations in recurrent/metastatic cervical cancer: The NRG Oncology/Gynecologic Oncology Group-0240 National Institutes of Health Beau Biden Cancer Moonshot. SGO 2023. March 25-28, 2023.